Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (21)

2024

  1. DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain

    Viruses, Vol. 16, Núm. 2

2023

  1. EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci

    International Journal of Antimicrobial Agents, Vol. 62, Núm. 3

2020

  1. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients

    Medicine (United States), Vol. 98, Núm. 32

2018

  1. No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients

    PLoS ONE, Vol. 13, Núm. 9

2016

  1. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens

    PLoS ONE, Vol. 11, Núm. 2

2014

  1. Causas que justifican el cambio del tratamiento antirretroviral en personas con infección por el VIH en España (años 2010-2011). Estudio SWITCH AUDIT

    Revista Espanola de Quimioterapia, Vol. 27, Núm. 2, pp. 93-97

2012

  1. Programas de optimización de uso de antimicrobianos (PROA) en hospitales españoles: documento de consenso GEIH-SEIMC, SEFH y SEMPSPH

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 30, Núm. 1

  2. Programas de optimización de uso de antimicrobianos (PROA) en hospitales españoles: documento de consenso GEIH-SEIMC, SEFH y SEMPSPH

    Farmacia Hospitalaria, Vol. 36, Núm. 1

2011

  1. Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100mg once daily in HIV/Hepatitis C Virus-Coinfected Patients

    AIDS Patient Care and STDs, Vol. 25, Núm. 7, pp. 395-402

  2. Programs to optimize antimicrobial use (PROA) in Spanish hospitals: GEIH-SEIMC, SEFH and SEMPSPH consensus document

    Medicina Preventiva, Vol. 17, Núm. 3, pp. 29-39

2010

  1. Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: A multicentre prospective study

    AIDS Research and Therapy, Vol. 7

2009

  1. Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: Effect of hepatitis virus co-infection and pre-existing fibrosis

    Journal of Antimicrobial Chemotherapy, Vol. 63, Núm. 1, pp. 178-183

2008

  1. Liver toxicity of antiretroviral combinations including atazanavir/ ritonavir in patients co-infected with HIV and hepatitis viruses: Impact of pre-existing liver fibrosis

    Journal of Antimicrobial Chemotherapy, Vol. 61, Núm. 4, pp. 925-932

  2. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313

2007

  1. Ensayo clínico aleatorizado para evaluar tres pautas cortas de tratamiento de la infección latente tuberculosa en pacientes infectados por el VIH

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 25, Núm. 5, pp. 305-310

2005

  1. Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naïve patients: The VESD study

    HIV Clinical Trials, Vol. 6, Núm. 6, pp. 320-328

2000

  1. Prevalence of primary mutations in human immunodeficiency virus with resistance to nucleoside analogues in naive human immunodeficiency virus-infected patients from Andalucía (Spain)

    Medicina Clinica, Vol. 115, Núm. 11, pp. 423-425

1999

  1. Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B

    AIDS, Vol. 13, Núm. 9, pp. 1063-1069

1998

  1. Comparative study of bacteremias caused by Enterococcus spp. with and without High-level resistance to gentamicin

    Journal of Clinical Microbiology, Vol. 36, Núm. 2, pp. 520-525